ATRX is altered in 36.48% of astrocytoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ATRX status and astrocytoma as inclusion criteria, 1 is phase 2 (0 open) [3].

EGFR is altered in 10.09% of astrocytoma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains EGFR status and astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERBB2 is altered in 1.22% of astrocytoma patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERBB4 is altered in 1.22% of astrocytoma patients [2].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB4 status and astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

IDH1 is altered in 41.98% of astrocytoma patients [2].

IDH1 is an inclusion eligibility criterion in 3 clinical trials for astrocytoma, of which 3 are open and 0 are closed. Of the trials that contain IDH1 status and astrocytoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].

IDH2 is altered in 1.26% of astrocytoma patients [2].

IDH2 is an inclusion eligibility criterion in 2 clinical trials for astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 status and astrocytoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [3].

TERT is altered in 2.96% of astrocytoma patients [2].

TERT is an inclusion eligibility criterion in 1 clinical trial for astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains TERT status and astrocytoma as inclusion criteria, 1 is phase 2 (0 open) [3].